Form 4: Verona Pharma CFO Mark Hahn Reports Significant Equity Transactions and New RSU Award

Verona Pharma plc's Chief Financial Officer, Mark W. Hahn, reported the vesting of performance-based Restricted Share Units and a subsequent sale of shares to cover tax obligations, alongside a new RSU award.

Summary

• Mark W. Hahn, Chief Financial Officer of Verona Pharma plc (VRNA), reported multiple equity transactions.
• On July 7, 2025, 229,512 Ordinary Shares were acquired at a price of $0, resulting from the vesting of previously reported Restricted Share Units (RSUs).
• Following this acquisition, Mr. Hahn's beneficial ownership of Ordinary Shares was 12,508,504.
• On July 8, 2025, 90,320 Ordinary Shares were disposed of at a price of $11.4413 per share. This disposition was to satisfy tax withholding obligations related to the RSU vesting.
• After the tax-related disposition, Mr. Hahn's beneficial ownership of Ordinary Shares was 12,418,184.
• On July 7, 2025, Mr. Hahn was awarded 675,048 new performance-based Restricted Share Units (RSUs).
• Also on July 7, 2025, 229,512 Restricted Share Units were disposed of, corresponding to the vested shares.
• The RSUs were earned because the Board of Directors determined that certain performance metrics for Q2 2025 had been achieved.
• 34% of the newly earned RSUs vested immediately on the determination date, with the remaining shares vesting in equal quarterly installments over a two-year period on November 1, February 1, May 1, and August 1, contingent on continued service.
• Each American Depositary Share (ADS) represents eight Ordinary Shares of Verona Pharma plc.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the significant award of new performance-based Restricted Share Units, indicating the achievement of Q2 2025 performance metrics. The share disposition is a neutral event, being solely for tax withholding purposes.

Positives

• The award of 675,048 new performance-based Restricted Share Units to the CFO indicates the achievement of specific Q2 2025 performance metrics as determined by the Board of Directors.
• The vesting of 229,512 Ordinary Shares from previously reported RSUs demonstrates the realization of prior equity compensation.

Negatives

• The disposition of 90,320 Ordinary Shares was solely to cover tax withholding obligations, not a voluntary sale for profit, which is a standard consequence of RSU vesting.

Future Outlook

The vesting schedule for the newly awarded Restricted Share Units indicates future equity compensation for the CFO, contingent on continued service to the company over the next two years, with vesting occurring quarterly on November 1, February 1, May 1, and August 1.

Management Comments

• The RSUs were earned upon the determination by the Board of Directors of the Issuer that certain performance metrics related to Q2 2025 had been achieved.

Industry Context

This Form 4 filing details routine insider equity transactions for a pharmaceutical company's CFO, reflecting standard executive compensation practices tied to performance and tax obligations. It does not provide information on broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders: Provides transparency into the equity compensation and holdings of a key executive, demonstrating alignment of management incentives with company performance through performance-based RSU awards. The tax-related sale is a routine event.

Next Steps

• Continued quarterly vesting of the remaining 66% of the newly awarded Restricted Share Units over a two-year period, contingent on the CFO's continued service.

Key Dates

Keywords

Verona Pharma, VRNA, SEC Form 4, Insider Trading, Restricted Share Units, RSU Vesting, Equity Compensation, Chief Financial Officer, Mark Hahn, Share Disposition, Tax Withholding, Performance Metrics, American Depositary Shares